FDA accepts NDA for MNK-795 oral formulation

Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.  MNK-795 is a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.  MNK-795 is formulated with Depomed's Acuform® drug delivery technology.      

The NDA acceptance triggers a $5 million milestone payment to Depomed under a license agreement between Depomed and Mallinckrodt.  Depomed is also entitled to an additional milestone payment upon approval of the NDA and high single digit royalties on net sales of MNK-795, if approved.

The FDA granted the NDA a priority review, a designation given to drugs that, if approved, offer significant improvements in the safety or effectiveness of the treatment when compared to standard applications. 

"We are pleased that the FDA has accepted the NDA for MNK-795 for filing, and we look forward to potential approval of this product," said Jim Schoeneck, President and CEO of Depomed.  "Depomed's proprietary Acuform drug-delivery technology is also being used (under similar milestone and royalty terms) by Mallinckrodt in development of another pipeline product that is being studied in patients with acute, moderate to severe pain.  Should either or both of these products be approved, we believe that the combination of milestones and royalties on net sales can make a significant contribution to Depomed's future revenues."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ultra-processed foods dominate children's diets from toddlerhood to middle childhood